Analyst Price Target is $21.00
▲ +764.20% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PLx Pharma in the last 3 months. The average price target is $21.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 764.20% upside from the last price of $2.43.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in PLx Pharma. This Buy consensus rating has held steady for over two years.
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.